Asthma ExacerbationsNCT06621056
A Cohort Study of Risk Factors and Prognosis for Frequent Acute Asthma Exacerbations Phenotype
An observational study of Asthma Exacerbations, run by Peking University Third Hospital at 1 site in China.
Trial summary
Acute asthma exacerbations are an important public health problem and a major cause of disease progression and healthcare burden for people with asthma. Frequent acute exacerbations are likely to be a distinct asthma phenotype. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Asthma Exacerbations
- What is being tested?
- not applicable for observational research
- How many people
- 300 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2022to 31 Dec 2025
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with asthma attending the outpatient clinic of the Department of Respiratory and Critical Care Medicine of Peking University Third Hospital met the diagnostic criteria for asthma proposed by the guidelines for the prevention and treatment of bronchial asthma
Who may be able to join
- Patients with asthma attending the outpatient clinic of the Department of Respiratory and Critical Care Medicine of Peking University Third Hospital met the diagnostic criteria for asthma proposed by the guidelines for the prevention and treatment of bronchial asthma.
Who cannot join
- Combination of chronic obstructive pulmonary disease, bronchiectasis, pneumonia, obstructive sleep apnea hypoventilation syndrome, malignancy; combination of various acute and chronic respiratory failure; combination of severe cardiovascular disease; pregnant women.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Peking University third hospital
Beijing, Beijing Municipality, 100191
Chun Chang, 010-82265562, doudou1977bysy@sina.com
About this study
Acute asthma exacerbations are an important public health problem and a major cause of disease progression and healthcare burden for people with asthma. Frequent acute exacerbations are likely to be a distinct asthma phenotype. Further research is needed to identify risk factors for frequent acute exacerbations, but previous studies have mostly been cross-sectional studies at a single time point or prospective studies based on smaller sample sizes. Moreover, most of the studies on frequent acute exacerbations have been conducted in severe or refractory asthma, whereas a certain proportion of non-severe asthmatics may also experience frequent acute exacerbations, the risk factors of which remain to be further evaluated. The main objectives of this project are to compare the baseline clinical, inflammatory, pathophysiological, comorbidities, environmental pollutants and meteorological exposure characteristics of patients with frequent acute exacerbations and those with non-frequent acute exacerbations irrespective of asthma severity, and to develop a disease prediction model for frequent acute exacerbations; and to develop a cohort of patients with frequent acute exacerbations of asthma, observe their prognosis and response to treatment, and search for prognostic factors associated with them. The successful implementation of this study will help in the early identification of patients with frequent acute exacerbations, clarify the factors associated with poor prognosis in this group of patients, and thus provide an individualized plan for the treatment and prevention of this type of patients, which is of great significance in achieving good asthma control, reducing the burden of disease, decreasing the cost of healthcare, and saving clinical healthcare resources and costs.
Read the detailed description
Asthma is an important respiratory disease. Asthma affects 1-18% of the population worldwide.The prevalence of asthma in adults ≥20 years old in China is 4.2% , numbering 45.7 million. An acute asthma exacerbation is defined as a rapid increase in symptoms such as wheezing, shortness of breath, chest tightness, and cough in a short period of time, and deterioration of lung function that requires additional reliever medications to treat. Acute asthma exacerbations are important events in the course of poorly controlled asthma, leading to increased mortality, decreased quality of life and extensive use of health care resources. Reducing the frequency of acute asthma exacerbations is an important principle of asthma treatment. It has been found that some patients with asthma are prone to acute exacerbations and these patients develop a stable phenotype. Compared to patients with infrequent acute exacerbations, asthma patients with frequent exacerbations are characterized by higher doses of inhaled glucocorticoids and/or oral hormones, poorer asthma control, lower quality of life, increased CRP and sputum eosinophils, more rapid decline in lung function, and a greater likelihood of continuing to have frequent acute exacerbations thereafter. A high proportion of patients with frequent acute exacerbations are present in patients with asthma of varying severity. Although treatment adherence and self-management skills are thought to be associated with acute asthma exacerbations, however, a higher proportion of asthma patients with good adherence and self-management skills still seem to be prone to acute exacerbations . Furthermore, reduction in asthma symptoms does not always correspond to the number or severity of acute attacks. Unlike what has been previously observed in severe asthma, there was no significant correlation between frequent acute exacerbations of asthma and asthma duration, age of onset, race, and socioeconomic background. The above studies suggest that frequent asthma exacerbations may represent a distinct asthma phenotype and that the underlying mechanisms of asthma severity and frequent acute exacerbations may be different. We need more research on the pathogenic mechanisms and treatments for frequent acute exacerbations.
Studies on risk factors for frequent acute exacerbations of asthma have yielded inconsistent results. Some studies have shown that asthma severity is an independent risk factor for frequent acute asthma exacerbations. However, other findings show that when patients are compliant with treatment, there are no specific characteristics that distinguish frequent acute exacerbations from infrequent acute exacerbations of the same asthma severity. Poorly controlled asthma also greatly increases the risk of acute exacerbations, but inconsistencies between the current level of control and the risk of acute exacerbations have also been reported. A significant proportion of patients with mild to moderate asthma who have well controlled asthma have frequent exacerbations, suggesting that the underlying mechanisms of baseline disease control and acute exacerbations may be driven by different factors in patients with mild to moderate asthma, and that a reduction in asthma symptoms does not always coincide with the number or severity of acute exacerbations. The pathophysiological mechanisms that cause frequent asthma exacerbations are unclear, and a few studies have explored the inflammatory mechanisms underlying frequent asthma exacerbations, with a multicenter cohort study of severe asthma showing that blood eosinophils were associated with asthma with a predisposition to acute exacerbations. When asthma treatment is aimed at minimizing airway eosinophil counts, the occurrence of frequent exacerbations can be prevented in moderate to severe asthma.High FeNO levels are also a risk factor for frequent acute exacerbations. However, sputum eosinophil percentages below 2% have also been reported in patients with frequent exacerbations. Mechanisms related to viral infection may also play a role in frequent acute attacks. One study evaluated the concentrations of interferon-gamma protein 10 (IP-10) and neopterin, and the results compared to the stable phase suggested that these two biomarkers of inflammation involved in viral infection were increased during acute episodes. However, the study did not confirm a difference in the concentrations of the two biomarkers between frequent and infrequent acute episodes. There is still a need to identify biomarkers, which may help to predict frequent acute episodes.
In summary, frequent acute exacerbations are likely to be a distinct asthma phenotype. Further studies are needed to identify risk factors for frequent acute exacerbations, but previous studies have mostly been cross-sectional studies at a single time point or prospective studies based on smaller sample sizes. Moreover, most of the studies on frequent acute exacerbations have been conducted in severe or refractory asthma, whereas a certain proportion of patients with nonsevere asthma may also have frequent acute exacerbations, and their risk factors still need to be further evaluated; in addition, previous studies have rarely looked at the effect of comorbidities on frequent acute exacerbations; furthermore, there have been no prospective studies to look at the prognosis of patients with frequent acute exacerbations and the response to treatments and prognostic factors associated with such attacks. Finally, the pathophysiologic mechanisms underlying frequent acute exacerbations of asthma require further investigation.
Therefore, the main objectives of this study were to compare the baseline clinical, inflammatory, pathophysiologic, comorbid, and environmental characteristics of patients with frequent acute exacerbations and those with infrequent acute exacerbations, regardless of asthma severity, and to develop a predictive model for frequent acute exacerbations; and to develop a cohort of patients with frequent acute exacerbations of asthma, to observe their prognosis and response to therapy, and to search for prognostic-related factors. The successful implementation of this study will help early identification of patients with frequent acute exacerbations, clarify the factors associated with poor prognosis in this group of patients, and thus provide individualized solutions for the treatment and prevention of patients with this type of asthma; exploring the inflammatory mechanisms of frequent acute exacerbations of asthma will help to elucidate the pathogenesis of this subtype, and to discover new specific therapeutic targets for this subtype.
- Conditions
- Asthma Exacerbations
- Being tested
- not applicable for observational research
- Keywords
- asthma
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
not applicable for observational researchOther
This is an observational research and has no intervention
| Study group | Role | What they receive |
|---|---|---|
| asthma with frequent exacerbations | asthma with frequent exacerbations Receives: Other: not applicable for observational research | |
| asthma without frequent exacerbations | asthma without frequent exacerbations Receives: Other: not applicable for observational research |
What is being measured
The primary outcome is the main question the study is designed to answer.
acute asthma exacerbation
An acute asthma exacerbation is a condition in which the patient\'s symptoms of wheezing, shortness of breath, chest tightness, and coughing appear in a short period of time or worsen rapidly, and lung function deteriorates, requiring the administration of additional reliever medications for treatment
Measured: baseline and during 1 year follow-up
Secondary outcomes (4)
total allergen IgE, allergen-specific IgE,
At baseline, demographic characteristics, asthma severity, asthma control level, comorbidities, lung function, peripheral blood eosinophil count and percentage, FENO, total allergen IgE, allergen-specific IgE, lung CT morphology, and exhaled breath condensate inflammation were collected; total allergen IgE, peripheral blood eosinophil count and percentage, FENO, exhaled breath condensate inflammation, and lung function were followed up at every 3 months; and lung CT morphology was reviewed at 1 year of follow-up; Outdoor environmental pollutants and meteorological information of the place of residence during 1 year of follow-up.
Measured: baseline and during 1 year follow-up
peripheral blood and sputum eosinophil count and percentage
At baseline, demographic characteristics, asthma severity, asthma control level, comorbidities, lung function, peripheral blood eosinophil count and percentage, FENO, total allergen IgE, allergen-specific IgE, lung CT morphology, and exhaled breath condensate inflammation were collected; total allergen IgE, peripheral blood eosinophil count and percentage, FENO, exhaled breath condensate inflammation, and lung function were followed up at every 3 months; and lung CT morphology was reviewed at 1 year of follow-up; Outdoor environmental pollutants and meteorological information of the place of residence during 1 year of follow-up.
Measured: baseline and during 1 year follow-up
lung function
At baseline, demographic characteristics, asthma severity, asthma control level, comorbidities, lung function, peripheral blood eosinophil count and percentage, FENO, total allergen IgE, allergen-specific IgE, lung CT morphology, and exhaled breath condensate inflammation were collected; total allergen IgE, peripheral blood eosinophil count and percentage, FENO, exhaled breath condensate inflammation, and lung function were followed up at every 3 months; and lung CT morphology was reviewed at 1 year of follow-up; Outdoor environmental pollutants and meteorological information of the place of residence during 1 year of follow-up.
Measured: baseline and during 1 year follow-up
lung CT morphology
At baseline, demographic characteristics, asthma severity, asthma control level, comorbidities, lung function, peripheral blood eosinophil count and percentage, FENO, total allergen IgE, allergen-specific IgE, lung CT morphology, and exhaled breath condensate inflammation were collected; total allergen IgE, peripheral blood eosinophil count and percentage, FENO, exhaled breath condensate inflammation, and lung function were followed up at every 3 months; and lung CT morphology was reviewed at 1 year of follow-up; Outdoor environmental pollutants and meteorological information of the place of residence during 1 year of follow-up.
Measured: baseline and during 1 year follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start1 Jan 2022
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Asthma ExacerbationsStudies of the same condition, open and under way.
- More trials run by Peking University Third HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Peking University Third Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06621056
- Sponsor's protocol ID
- M2022148
- Other IDs
- BYSYDL2021020
- Status last verified
- Sep 2024
- First submitted
- 19 Sep 2024
- Last updated
- 1 Oct 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data involve patient privacy
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Cohort Study of Risk Factors and Prognosis for Frequent Acute Asthma Exacerbations Phenotype
- ClinicalTrials.gov ID
- NCT06621056
- Acronym / sponsor ID
- M2022148
- Conditions
- Asthma Exacerbations
- Keywords
- asthma
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Peking University Third HospitalUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute asthma exacerbations are an important public health problem and a major cause of disease progression and healthcare burden for people with asthma. Frequent acute exacerbations are likely to be a distinct asthma phenotype. Further research is needed to identify risk factors for frequent acute exacerbations, but previous studies have mostly been cross-sectional studies at a single time point or prospective studies based on smaller sample sizes. Moreover, most of the studies on frequent acute exacerbations have been conducted in severe or refractory asthma, whereas a certain proportion of non-severe asthmatics may also experience frequent acute exacerbations, the risk factors of which remain to be further evaluated. The main objectives of this project are to compare the baseline clinical, inflammatory, pathophysiological, comorbidities, environmental pollutants and meteorological exposure characteristics of patients with frequent acute exacerbations and those with non-frequent acute exacerbations irrespective of asthma severity, and to develop a disease prediction model for frequent acute exacerbations; and to develop a cohort of patients with frequent acute exacerbations of asthma, observe their prognosis and response to treatment, and search for prognostic factors associated with them. The successful implementation of this study will help in the early identification of patients with frequent acute exacerbations, clarify the factors associated with poor prognosis in this group of patients, and thus provide an individualized plan for the treatment and prevention of this type of patients, which is of great significance in achieving good asthma control, reducing the burden of disease, decreasing the cost of healthcare, and saving clinical healthcare resources and costs.
Detailed description
Asthma is an important respiratory disease. Asthma affects 1-18% of the population worldwide.The prevalence of asthma in adults ≥20 years old in China is 4.2% , numbering 45.7 million. An acute asthma exacerbation is defined as a rapid increase in symptoms such as wheezing, shortness of breath, chest tightness, and cough in a short period of time, and deterioration of lung function that requires additional reliever medications to treat. Acute asthma exacerbations are important events in the course of poorly controlled asthma, leading to increased mortality, decreased quality of life and extensive use of health care resources. Reducing the frequency of acute asthma exacerbations is an important principle of asthma treatment. It has been found that some patients with asthma are prone to acute exacerbations and these patients develop a stable phenotype. Compared to patients with infrequent acute exacerbations, asthma patients with frequent exacerbations are characterized by higher doses of inhaled glucocorticoids and/or oral hormones, poorer asthma control, lower quality of life, increased CRP and sputum eosinophils, more rapid decline in lung function, and a greater likelihood of continuing to have frequent acute exacerbations thereafter. A high proportion of patients with frequent acute exacerbations are present in patients with asthma of varying severity. Although treatment adherence and self-management skills are thought to be associated with acute asthma exacerbations, however, a higher proportion of asthma patients with good adherence and self-management skills still seem to be prone to acute exacerbations . Furthermore, reduction in asthma symptoms does not always correspond to the number or severity of acute attacks. Unlike what has been previously observed in severe asthma, there was no significant correlation between frequent acute exacerbations of asthma and asthma duration, age of onset, race, and socioeconomic background. The above studies suggest that frequent asthma exacerbations may represent a distinct asthma phenotype and that the underlying mechanisms of asthma severity and frequent acute exacerbations may be different. We need more research on the pathogenic mechanisms and treatments for frequent acute exacerbations.
Studies on risk factors for frequent acute exacerbations of asthma have yielded inconsistent results. Some studies have shown that asthma severity is an independent risk factor for frequent acute asthma exacerbations. However, other findings show that when patients are compliant with treatment, there are no specific characteristics that distinguish frequent acute exacerbations from infrequent acute exacerbations of the same asthma severity. Poorly controlled asthma also greatly increases the risk of acute exacerbations, but inconsistencies between the current level of control and the risk of acute exacerbations have also been reported. A significant proportion of patients with mild to moderate asthma who have well controlled asthma have frequent exacerbations, suggesting that the underlying mechanisms of baseline disease control and acute exacerbations may be driven by different factors in patients with mild to moderate asthma, and that a reduction in asthma symptoms does not always coincide with the number or severity of acute exacerbations. The pathophysiological mechanisms that cause frequent asthma exacerbations are unclear, and a few studies have explored the inflammatory mechanisms underlying frequent asthma exacerbations, with a multicenter cohort study of severe asthma showing that blood eosinophils were associated with asthma with a predisposition to acute exacerbations. When asthma treatment is aimed at minimizing airway eosinophil counts, the occurrence of frequent exacerbations can be prevented in moderate to severe asthma.High FeNO levels are also a risk factor for frequent acute exacerbations. However, sputum eosinophil percentages below 2% have also been reported in patients with frequent exacerbations. Mechanisms related to viral infection may also play a role in frequent acute attacks. One study evaluated the concentrations of interferon-gamma protein 10 (IP-10) and neopterin, and the results compared to the stable phase suggested that these two biomarkers of inflammation involved in viral infection were increased during acute episodes. However, the study did not confirm a difference in the concentrations of the two biomarkers between frequent and infrequent acute episodes. There is still a need to identify biomarkers, which may help to predict frequent acute episodes.
In summary, frequent acute exacerbations are likely to be a distinct asthma phenotype. Further studies are needed to identify risk factors for frequent acute exacerbations, but previous studies have mostly been cross-sectional studies at a single time point or prospective studies based on smaller sample sizes. Moreover, most of the studies on frequent acute exacerbations have been conducted in severe or refractory asthma, whereas a certain proportion of patients with nonsevere asthma may also have frequent acute exacerbations, and their risk factors still need to be further evaluated; in addition, previous studies have rarely looked at the effect of comorbidities on frequent acute exacerbations; furthermore, there have been no prospective studies to look at the prognosis of patients with frequent acute exacerbations and the response to treatments and prognostic factors associated with such attacks. Finally, the pathophysiologic mechanisms underlying frequent acute exacerbations of asthma require further investigation.
Therefore, the main objectives of this study were to compare the baseline clinical, inflammatory, pathophysiologic, comorbid, and environmental characteristics of patients with frequent acute exacerbations and those with infrequent acute exacerbations, regardless of asthma severity, and to develop a predictive model for frequent acute exacerbations; and to develop a cohort of patients with frequent acute exacerbations of asthma, to observe their prognosis and response to therapy, and to search for prognostic-related factors. The successful implementation of this study will help early identification of patients with frequent acute exacerbations, clarify the factors associated with poor prognosis in this group of patients, and thus provide individualized solutions for the treatment and prevention of patients with this type of asthma; exploring the inflammatory mechanisms of frequent acute exacerbations of asthma will help to elucidate the pathogenesis of this subtype, and to discover new specific therapeutic targets for this subtype.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| asthma with frequent exacerbations | – | Other: not applicable for observational researchasthma with frequent exacerbations |
| asthma without frequent exacerbations | – | Other: not applicable for observational researchasthma without frequent exacerbations |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with asthma attending the outpatient clinic of the Department of Respiratory and Critical Care Medicine of Peking University Third Hospital met the diagnostic criteria for asthma proposed by the guidelines for the prevention and treatment of bronchial asthma
Key inclusion criteria (1 listed)
- Patients with asthma attending the outpatient clinic of the Department of Respiratory and Critical Care Medicine of Peking University Third Hospital met the diagnostic criteria for asthma proposed by the guidelines for the prevention and treatment of bronchial asthma.
Key exclusion criteria (1 listed)
- Combination of chronic obstructive pulmonary disease, bronchiectasis, pneumonia, obstructive sleep apnea hypoventilation syndrome, malignancy; combination of various acute and chronic respiratory failure; combination of severe cardiovascular disease; pregnant women.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| not applicable for observational researchThis is an observational research and has no intervention | Other | asthma with frequent exacerbations, asthma without frequent exacerbations |
Primary outcome
acute asthma exacerbation
Time frame: baseline and during 1 year follow-up
An acute asthma exacerbation is a condition in which the patient\'s symptoms of wheezing, shortness of breath, chest tightness, and coughing appear in a short period of time or worsen rapidly, and lung function deteriorates, requiring the administration of additional reliever medications for treatment
4 secondary outcomes
total allergen IgE, allergen-specific IgE,
Time frame: baseline and during 1 year follow-up
peripheral blood and sputum eosinophil count and percentage
Time frame: baseline and during 1 year follow-up
lung function
Time frame: baseline and during 1 year follow-up
lung CT morphology
Time frame: baseline and during 1 year follow-up
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2024.
- Individual participant dataSharing planned: No. Individual participant data involve patient privacy
Related trials for Asthma Exacerbations
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
RecruitingPhase 2
Rademikibart IV for Acute Asthma and COPD Exacerbation
Asthma Acute, COPD Exacerbation Acute
Active, not recruitingPhase 3
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Asthma
Not yet recruiting
Bilevel Positive Airway Pressure (BPAP) for Severe Asthma
Pediatric Asthma, Acute Asthma
Recruiting
Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects
Asthma Acute
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Asthma Exacerbations, run by Peking University Third Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Chun Chang (19800300860, doudou1977bysy@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
acute asthma exacerbation (time frame: baseline and during 1 year follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2024.